Impact of COVID-19 on neurological, psychological and other mental health outcomes

Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, October 11, 2021
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Twitter, Forward-looking statement, Impact of COVID-19 on neurological, psychological and other mental health outcomes, Chemokine, Graft-versus-host disease, MedRxiv, COVID-19, Manuscript, Goal, Health, LinkedIn, Rheumatoid arthritis, SEC, Pressure, ICU, Knowledge, Judgement, Francis M. Shea, GM-CSF, Sung, Journal of Medical Economics, Patient, GM, Risk, Nasdaq, Granulocyte-macrophage colony-stimulating factor, Pharmaceutical industry

These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.

Key Points: 
  • These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • Health Outcomes and economic burden of hospitalized COVID-19 patients in the United States.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Nineteen Percent of Asymptomatic COVID-19 Patients Develop Long-Haul COVID

Retrieved on: 
Tuesday, June 15, 2021
Health sciences, Health, COVID-19, Medicine, Long Covid, Occupational safety and health, PASC, Medical research, Impact of COVID-19 on neurological, psychological and other mental health outcomes, COVID-19 drug development

Names for such post-COVID conditions include not only long-haul COVID but long COVID, post-COVID syndrome or post-acute sequelae of COVID-19 or of SARS-CoV-2 (PASC).

Key Points: 
  • Names for such post-COVID conditions include not only long-haul COVID but long COVID, post-COVID syndrome or post-acute sequelae of COVID-19 or of SARS-CoV-2 (PASC).
  • The odds of death 30 days or more after initial diagnosis with COVID-19 were 46 times higher for patients who were hospitalized with COVID-19 and discharged than patients who had not been hospitalized.
  • Of COVID-19 patients who were hospitalized and discharged, 0.5 percent died 30 days or more after their initial diagnosis.
  • In addition to asymptomatic patients, those presenting with post-COVID conditions included 27.5 percent of COVID-19 patients who were symptomatic but not hospitalized, 50 percent of hospitalized patients and 23.2 percent of all patients who had COVID-19.